|
**Overview**: Chimerism Myeloid CD15 Panel**Introduction**: The Chimerism Myeloid CD15 Panel is a diagnostic tool designed to monitor myeloid cell transplant engraftment using whole blood samples. In India, hematopoietic stem cell transplantation (HSCT) is increasingly performed for hematological malignancies (leukemia, lymphoma) and disorders (thalassemia, aplastic anemia), with ~5,000â€"10,000 transplants/year, mostly allogeneic. Myeloid lineage chimerism (CD15+ cells) assesses donor cell engraftment post-transplant. High morbidity from graft failure or relapse in rural/low-SES patients, limited transplant centers, delayed monitoring leading to poor outcomes. Per hematology practices aligned with ICMR and Indian Society of Blood and Marrow Transplantation guidelines, the test employs flow cytometry for CD15+ cell chimerism over 1-2 days with high sensitivity/specificity, valuable for early detection of mixed chimerism or rejection. This diagnostic falls under post-transplant evaluation and targets HSCT recipients, addressing accurate monitoring to guide immunosuppression or donor lymphocyte infusion. With elevated morbidity due to under-monitoring in resource-limited settings, the test supports public health efforts by enabling precise engraftment assessment and reducing relapse/graft failure. Its whole blood-based approach ensures reliable detection in India's transplant programs.**Other Names**: Chimerism CD15 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology, compliant with 2025 standards.**Historical Milestone**: Flow-based lineage-specific chimerism; in India, standard in major transplant centers.**Purpose**: The test monitors 3 parameters including CD15+ cell chimerism to guide myeloid engraftment assessment, detect donor dominance, inform post-transplant management.**Test Parameters**: 1. CD15+ Cell Chimerism, 2. Donor DNA, 3. Recipient DNA.**Pretest Condition**: No fasting required; patients should have recent HSCT with myeloid monitoring need.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow cytometry).**Medical History**: Patients should provide details on transplant type/date, conditioning, GVHD status, donor match.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of poor engraftment including relapse, benefits of monitoring, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High donor chimerism indicates engraftment; mixed/low indicates risk, necessitating specialist input.**Specialist Consultation**: Transplant hematologists should be consulted for management.**Additional Supporting Tests**: Full chimerism, STR PCR for confirmation.**Test Limitations**: Lineage-specific only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, HSCT Studies India 2023. |
